Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).

MLA

Edelmann F, et al. “Rationale and Design of the ‘Aldosterone Receptor Blockade in Diastolic Heart Failure’ Trial: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Determine the Effects of Spironolactone on Exercise Capacity and Diastolic Function in Patients with Symptomatic Diastolic Heart Failure (Aldo-DHF).” European Journal of Heart Failure, vol. 12, no. 8, Aug. 2010, pp. 874–82. EBSCOhost, https://doi.org/10.1093/eurjhf/hfq087.

APA

Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B, Edelmann, F., Schmidt, A. G., Gelbrich, G., Binder, L., Herrmann-Lingen, C., Halle, M., Hasenfuss, G., Wachter, R., & Pieske, B. (2010). Rationale and design of the “aldosterone receptor blockade in diastolic heart failure” trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure, 12(8), 874–882. https://doi.org/10.1093/eurjhf/hfq087

Chicago

Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, et al. 2010. “Rationale and Design of the ‘Aldosterone Receptor Blockade in Diastolic Heart Failure’ Trial: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Determine the Effects of Spironolactone on Exercise Capacity and Diastolic Function in Patients with Symptomatic Diastolic Heart Failure (Aldo-DHF).” European Journal of Heart Failure 12 (8): 874–82. doi:10.1093/eurjhf/hfq087.